A recent research has revealed that a cancer drug can help in reversing the transplant rejection.

Research team led by Steve Woodle of University of Cincinnati (U-C) found that drug bortezomib, used for treating cancer of plasma cells can treat rejection episodes caused by antibodies that target transplanted kidneys. It can also reverse rejection episodes that did not respond to standard therapies.

Woodle said that we found a body of literature demonstrating that bortezomib works well in suppressing transplant rejection in the laboratory.

It’s a common medical belief that T-lymphocytes or T cells cause the rejection of transplanted organs. Researchers started this recent research to find agents that targeted plasma cells in 2005.

He added. "It has become clear that plasma cells and the antibodies they produce play a bigger role in rejection than previously thought, and the development of therapies targeting these cells has lagged."

Presently research team is conducting four clinical trials to test present research.